News | November 04, 2024
Briefs: Sun Pharmaceutical Industries and Biocon Biologics
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
Dilip Shanghvi to continue as the Executive Chairman of the Board
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Subscribe To Our Newsletter & Stay Updated
